[1]陈阳 赵庆豪 赵杰 吴永健.经导管主动脉瓣置换术时代慢性主动脉瓣反流诊治进展[J].心血管病学进展,2022,(1):1-6.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
　CHEN Yang,ZHAO Qinghao,SONG Guangyuan,et al.Diagnosis and Treatment of Chronic Aortic Regurgitation in Transcatheter Aortic Valve Replacement Era[J].Advances in Cardiovascular Diseases,2022,(1):1-6.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
点击复制

经导管主动脉瓣置换术时代慢性主动脉瓣反流诊治进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年1期
页码:
1-6
栏目:
出版日期:
2022-01-25

文章信息/Info

Title:
Diagnosis and Treatment of Chronic Aortic Regurgitation in Transcatheter Aortic Valve Replacement Era
作者:
陈阳 赵庆豪 赵杰 吴永健
(北京协和医学院 国家心血管病中心 中国医学科学院阜外医院 心内科,北京 100037)
Author(s):
CHEN Yang1; ZHAO Qinghao1;  SONG Guangyuan2;  WU Yongjian1
(1.Department of Cardiology,Fuwai Hospital,National Center for Cardiovascular Disease,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100037,China; 2. Heart Valve Intervention Center,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
关键词:
主动脉瓣反流; 多维度评估; 外科主动脉瓣置换术; 经导管主动脉瓣置换术
Keywords:
Aortic regurgitation; Multidimensional evaluation; Surgical aortic valve replacement; Transcatheter aortic valve replacement
DOI:
10.16806/j.cnki.issn.1004-3934.2022.01.001
摘要:
慢性主动脉瓣反流无症状期长，晚期预后差，最佳干预时机尚不明确。目前干预指征主要依据于症状和超声心动图的左室功能和扩张程度，而新影像学评估（磁共振、超声心动图新参数和计算机断层扫描评估等）及生物标志物可优化治疗决策。主动脉瓣反流患者药物治疗效果有限，不能替代或延迟手术治疗。目前大多数主动脉瓣反流患者仍首选外科主动脉瓣置换术，而经导管主动脉瓣置换术可用于外科高危患者。
Abstract:
Chronic aortic regurgitation(AR) has a long asymptomatic period and poor prognosis in the late stage,and the best time for intervention is not clear. At present,the intervention indications are mainly based on the symptoms and the left ventricular function and expansion degree of echocardiography,and new imaging evaluation(magnetic resonance,new echocardiographic parameters and computed tomography evaluation) and biomarkers can optimize treatment decision-making. The effect of drug treatment in AR patients is limited and cannot replace or delay the surgical treatment. At present,surgical aortic valve replacement is still the first choice for most AR patients,and transcatheter aortic valve replacement can be used for high-risk surgical patients.

参考文献/References:

[1] Otto CM,Nishimura RA,Bonow RO,et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2021,143(5):e72-e227.

[2] Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J,2021, Aug 28;ehab395.

DOI:10.1093/eurheartj/ehab395. Online ahead of print.

[3] Webb JG,Htun N. Transcatheter options for the treatment of noncalcified aortic regurgitation[J]. JACC Cardiovasc Interv,2015,8(14):1850-1853.

[4] Yang LT,Benfari G,Eleid M, et al. Contemporary differences between bicuspid and tricuspid aortic valve in chronic aortic regurgitation[J]. Heart,2021,107(11):916-924.

[5] Yang LT,Michelena HI,Maleszewski JJ,et al. Contemporary etiologies,mechanisms,and surgical approaches in pure native aortic regurgitation[J]. Mayo Clin Proc,2019,94(7):1158-1170.

[6] 陈阳,董徽,邓宇,等. 大动脉炎患者同步四肢血压及踝臂脉搏波速度特征[J]. 中国循环杂志,2020,35(5):481-486.

[7] Iung B,Baron G,Butchart EG,et al. A prospective survey of patients with valvular heart disease in Europe:The Euro Heart Survey on Valvular Heart Disease[J]. Eur Heart J,2003,24(13):1231-1243.

[8] Singh JP,Evans JC,Levy D,et al. Prevalence and clinical determinants of mitral,tricuspid,and aortic regurgitation(the Framingham Heart Study)[J]. Am J Cardiol,1999,83(6):897-902.

[9] Zhang B,Xu H,Zhang H,et al. Prognostic value of N-terminal pro-B-type natriuretic peptide in elderly patients with valvular heart disease[J]. J Am Coll Cardiol,2020,75(14):1659-1672.

[10] Kodali SK,Williams MR,Smith CR,et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement[J]. N Engl J Med,2012,366(18):1686-1695.

[11] Bonow RO,Lakatos E,Maron BJ,et al. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function[J]. Circulation,1991,84(4):1625-1635.

[12] Yang LT,Anand V,Zambito EI,et al. Association of echocardiographic left ventricular end-systolic volume and volume-derived ejection fraction with outcome in asymptomatic chronic aortic regurgitation[J]. JAMA Cardiol,2021,6(2):189-198.

[13] Nitenberg A,Foult JM,Antony I,et al. Coronary flow and resistance reserve in patients with chronic aortic regurgitation,angina pectoris and normal coronary arteries[J]. J Am Coll Cardiol,1988,11(3):478-486.

[14] Yang LT,Enriquez-Sarano M,Scott CG,et al. Concomitant mitral regurgitation in patients with chronic aortic regurgitation[J]. J Am Coll Cardiol,2020,76(3):233-246.

[15] 中华医学会心血管病学分会心血管影像学组,北京医学会心血管病学会影像学组. 中国成人心脏瓣膜病超声心动图规范化检查专家共识[J]. 中国循环杂志,2021,36(2):109-125.

[16] Postigo A,Perez-David E,Revilla A,et al. A comparison of the clinical efficacy of echocardiography and magnetic resonance for chronic aortic regurgitation[J]. Eur Heart J Cardiovasc Imaging,2020,Dec 17:jeaa338. DOI:10.1093/ehjci/jeaa338. Epub ahead of print.

[17] Lee JC,Branch KR,Hamilton-Craig C,et al. Evaluation of aortic regurgitation with cardiac magnetic resonance imaging:a systematic review[J]. Heart,2018,104(2):103-110.

[18] Kockova R,Linkova H,Hlubocka Z,et al. New imaging markers of clinical outcome in asymptomatic patients with severe aortic regurgitation[J]. J Clin Med,2019,8(10):1654.

[19] Jilaihawi H,Chen M,Webb J,et al. A bicuspid aortic valve imaging classification for the TAVR era[J]. JACC Cardiovasc Imaging,2016,9(10):1145-1158.

[20] Song I,Park JA,Choi BH,et al. Morphological and functional evaluation of quadricuspid aortic valves using cardiac computed tomography[J]. Korean J Radiol,2016,17(4):463-471.

[21] Koo HJ,Kang JW,Kim JA,et al. Functional classification of aortic regurgitation using cardiac computed tomography:comparison with surgical inspection[J]. Int J Cardiovasc Imaging,2018,34(8):1295-1303.

[22] Pibarot P,Hahn RT,Weissman NJ,et al. Assessment of paravalvular regurgitation following TAVR:a proposal of unifying grading scheme[J]. JACC Cardiovasc Imaging,2015,8(3):340-360.

[23] Pizarro R,Bazzino OO,Oberti PF,et al. Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chronic severe aortic regurgitation[J]. J Am Coll Cardiol,2011,58(16):1705-1714.

[24] Duchnowski P,Hryniewiecki T,Kusmierczyk M,et al. The usefulness of selected biomarkers in aortic regurgitation[J]. Cardiol J,2019,26(5):477-482.

[25] Elder DH,Wei L,Szwejkowski BR,et al. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation:a large population cohort study[J]. J Am Coll Cardiol,2011,58(20):2084-2091.

[26] Evangelista A,Tornos P,Sambola A,et al. Long-term vasodilator therapy in patients with severe aortic regurgitation[J]. N Engl J Med,2005,353(13):1342-1349.

[27] Sampat U,Varadarajan P,Turk R,et al. Effect of beta-blocker therapy on survival in patients with severe aortic regurgitation results from a cohort of 756 patients[J]. J Am Coll Cardiol,2009,54(5):452-457.

[28] Yang LT,Enriquez-Sarano M,Michelena HI,et al. Predictors of progression in patients with stage B aortic regurgitation[J]. J Am Coll Cardiol,2019,74(20):2480-2492.

[29] Dujardin KS,Enriquez-Sarano M,Schaff HV,et al. Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study[J]. Circulation,1999,99(14):1851-1857.

[30] Tornos P,Sambola A,Permanyer-Miralda G,et al. Long-term outcome of surgically treated aortic regurgitation:influence of guideline adherence toward early surgery[J]. J Am Coll Cardiol,2006,47(5):1012-1017.

[31] Baumgartner H,Iung B,Otto CM. Timing of intervention in asymptomatic patients with valvular heart disease[J]. Eur Heart J,2020,41(45):4349-4356.

[32] Chaliki HP,Mohty D,Avierinos JF,et al. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function[J]. Circulation,2002,106(21):2687-2693.

[33] Tornos MP,Olona M,Permanyer-Miralda G,et al. Clinical outcome of severe asymptomatic chronic aortic regurgitation:a long-term prospective follow-up study[J]. Am Heart J,1995,130(2):333-339.

[34] Yang LT,Michelena HI,Scott CG,et al. Outcomes in chronic hemodynamically significant aortic regurgitation and limitations of current guidelines[J]. J Am Coll Cardiol,2019,73(14):1741-1752.

[35] Arora S,Lahewala S,Zuzek Z,et al. Transcatheter aortic valve replacement in aortic regurgitation:The U.S. experience[J]. Catheter Cardiovasc Interv,2021,98(1):E153-E162.

[36] Takagi H,Hari Y,Kawai N,et al. Meta-analysis and meta-regression of transcatheter aortic valve implantation for pure native aortic regurgitation[J]. Heart Lung Circ,2020,29(5):729-741.

[37] 陈阳,王墨扬,牛冠男,等. 中国首例完全局部麻醉且无镇静下极简式经导管主动脉瓣置换术[J]. 中国循环杂志,2021,36(10):1027-1030.

[38] 陈阳，宋光远，牛冠男，等. 中国首例Silara?-Valve经导管主动脉瓣置换术[J]. 中国介入心脏病学杂志,2021,29(2):98-100.

[39] Phan K,Zhao DF,Wang N,et al. Transcatheter valve-in-valve implantation versus reoperative conventional aortic valve replacement:a systematic review[J]. J Thorac Dis,2016,8(1):E83-E93.

相似文献/References:

[1]达尼亚尔·迪力木拉提 施林 严飞.二叶式主动脉瓣发病机制及其临床诊治的研究进展[J].心血管病学进展,2023,(5):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
　Daniyar·Dilmurat,SHI Lin,YAN Fei.The PathogenesisClinical Diagnosis and Treatment of Bicuspid Aortic Valve[J].Advances in Cardiovascular Diseases,2023,(1):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
[2]刘雅靓 张静 苟中山 黄青霞 杨娅.二叶主动脉瓣的分型与临床意义[J].心血管病学进展,2024,(6):484.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.002]
　LIU Yaliang,ZHANG Jing,GOU Zhongshan,et al.Classification and Clinical Significance of Bicuspid Aortic Valve[J].Advances in Cardiovascular Diseases,2024,(1):484.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.002]

更新日期/Last Update: 2022-02-16